|Day Low/High||86.28 / 88.85|
|52 Wk Low/High||77.92 / 120.37|
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016.
Earnings reports will test the timeframe mettle for some investors and traders.
The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.
Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.
Verizon strikes a $4.8 billion deal to acquire Yahoo!'s core operations, while Tesla and SolarCity are closer to a merger agreement.
A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?
Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b switch studies evaluating Odefsey ® (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes.
The biotech juggernaut still has a lot going for it, especially at these levels.
But without negative divergences of consequence it’s hard to be bearish,
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.
Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.
The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.
An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.
Shares of Gilead (GILD) are up after Credit Suisse released a bullish note on the company.
Each bounce in the stock has been followed by a move to lower lows.
A look at who will be up and who will down this earnings season.
Cramer says there are several reasons why the market has risen since the Brexit vote.
They need to do something that makes them stand out as stocks you want to own, not avoid.